Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology
WJ Gradishar, BO Anderson, J Abraham, R Aft… - Journal of the National …, 2020 - jnccn.org
WJ Gradishar, BO Anderson, J Abraham, R Aft, D Agnese, KH Allison, SL Blair, HJ Burstein…
Journal of the National Comprehensive Cancer Network, 2020•jnccn.orgSeveral new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical
factors, the treatment selection primarily depends on the tumor biology (hormone-receptor
status and HER2-status). The NCCN Guidelines specific to the workup and treatment of
patients with recurrent/stage IV breast cancer are discussed in this article.
breast cancer, which have led to improvements in survival. In addition to patient and clinical
factors, the treatment selection primarily depends on the tumor biology (hormone-receptor
status and HER2-status). The NCCN Guidelines specific to the workup and treatment of
patients with recurrent/stage IV breast cancer are discussed in this article.
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
jnccn.org
以上显示的是最相近的搜索结果。 查看全部搜索结果